Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent combination chemotherapy and progression on regorafenib monotherapy.
Colorectal Cancer
DRUG: Regorafenib|DRUG: 5-FU|DRUG: Leucovorin
Progression Free Survival (PFS) at 2 Months, PFS at 2 months in mCRC patients who progress on regorafenib monotherapy and are treated with regorafenib and 5-FU/LV combination therapy., 2 months
Overall Survival Rate, Overall survival will be calculated from the day of first treatment until death, 1 years|Best Overall Response, This will be calculated from the day of first treatment dose until disease progression or death, whichever occurs earlier, 1-2 years|Number of Toxicities Due to Regorafenib and 5-FU/LV Combination Therapy, Number of toxicities due to combination therapy will be summarized by frequencies and grades of toxicities due to the combination therapy according to CTCAE 4.03 criteria, 1-2 years
This is a single arm open label pilot phase II trial of Regorafenib PO plus 5-FU/LV infusion in 15 mCRC patients who progressed on prior Regorafenib monotherapy as well as 5-FU containing chemotherapy combinations.The study will enroll mCRC patients with prior progression on standard multi-agent combination chemotherapy and progression on regorafenib monotherapy.